

Healthcare SaaS Valuation Report – Q1 2026

JANUARY 2026

Executive Summary – Q1 2026

<p>PUBLIC MEDIAN</p> <p>9.5X</p> <p>vs 6.7x General B2B SaaS</p>	<p>MARKET SIZE</p> <p>\$550B+</p> <p>Forecast 2026 (17.5% CAGR)</p>	<p>INTEGRATION PREMIUM</p> <p>70-85%</p> <p>For Native EHR Embeddedness</p>	<p>RCM MULTIPLE</p> <p>13X-16X</p> <p>For End-to-End SaaS+Payments</p>
--	---	---	--

✔ Structural Resilience

- **Clinical Criticality:** Software is non-discretionary for patient safety and billing. Integrated platforms command >14x multiples vs 5-7x for point solutions.
- **Regulatory Moats:** Complex mandates (HIPAA, HITRUST, Cures Act) create formidable barriers to entry, protecting incumbents from generalist competitors.
- **Recession Resistance:** Low churn rates and essential workflows maintain premium valuations even amidst broader economic volatility.

🔗 Strategic Catalysts

- **Value-Based Care:** With 65% of payments tied to outcomes by 2027, platforms proving clinical ROI (HEDIS/MIPS improvement) win pricing power.
- **Embedded Fintech:** "SaaS-plus-payments" models capturing 3-5% of claims volume generate superior unit economics and 45-55% gross margins.

The Healthcare Premium

Healthcare IT commands the highest sector-specific multiples (9.5x) in 2026. Value shifts decisively to "operating system" platforms that deeply integrate clinical workflows with financial rails, creating indispensability that point solutions cannot match.

Market Fundamentals & Growth Drivers

17.5%

ANNUAL GROWTH (CAGR)



Non-Discretionary Spend

Healthcare IT has decoupled from general software cycles. Investments are mission-critical for patient safety and revenue continuity, creating distinct valuation resilience compared to discretionary enterprise SaaS tools.

Regulatory Pull


Compliance is a growth engine, not just a cost. Mandates from HIPAA, HITRUST, and the 21st Century Cures Act force providers to adopt modern, interoperable platforms, creating a guaranteed replacement cycle for legacy systems.

Platform Consolidation

The market is shifting rapidly from point solutions to integrated suites. Platforms that solve clinical, financial, and operational challenges natively are winning share, forcing consolidation of fragmented vendor landscapes.

What Are Healthcare SaaS Companies Worth?

📈 +42% Premium vs General SaaS



Market Resilience

🛡️ Durability Premium

Healthcare contracts exhibit significantly lower churn during economic downturns compared to discretionary software, driving investor confidence and higher baseline multiples.

Core Workflow

🏥 Mission-Critical Status

Platforms essential for clinical workflows and patient safety create massive switching costs. This dependency protects recurring revenue and supports premium valuations.

Private Markets

⚖️ Premium Asset Parity

While the private median is 5.5x-6.5x, top-tier private assets achieve parity with public markets (9.5x+) driven by intense competition among private equity firms.

Valuation by Subsector (Q1 2026)

Clinical impact drives premium valuations, with AI-driven decision support and core EHR platforms commanding the highest multiples due to their influence on patient outcomes and revenue.

Subsector	EV/Revenue Range	EV/EBITDA Range	Key Value Driver
Clinical Decision Support	11.0x – 14.0x	28.0x – 34.0x	Outcome improvement metrics
EHR/EMR Platforms	10.0x – 13.0x	26.0x – 32.0x	Clinical integration depth
Revenue Cycle Management	9.0x – 12.0x	24.0x – 28.0x	Payment processing capture
Practice Management	8.0x – 10.0x	20.0x – 26.0x	Scheduling/Billing integration
Telehealth Platforms	7.5x – 9.5x	18.0x – 24.0x	Workflow embeddedness
Patient Engagement	7.0x – 9.0x	16.0x – 22.0x	Portal adoption rates


Clinical ROI Drives Premium Multiples

Clinical Decision Support tools leveraging AI to improve patient outcomes command the highest multiples (11-14x), surpassing traditional EHRs. This reflects the industry shift toward value-based care, where software must demonstrate direct reimbursement impact via HEDIS/MIPS improvement rather than just operational efficiency.

How EHR Integration Drives Multiples

↗ +90% Valuation Premium

WINDSOR DRAKE



Clinician Experience

Workflow Friction

Native integrations allow clinicians to access third-party functionality without leaving the EHR interface, eliminating the friction that is the primary cause of software abandonment.

Time-to-Value

FHIR Acceleration

Modern HL7 FHIR standards have dramatically reduced implementation timelines from 18 months to just 6-9 months, accelerating revenue recognition and customer success.

Defensibility

Retention Superiority

Deeply embedded workflows create sticky usage patterns. Native solutions demonstrate customer retention rates exceeding 95%, compared to significantly lower rates for standalone tools.

EHR Integration Levels: Timelines & Premiums

Deep, native integration with major EHR platforms is the single most significant valuation catalyst, driving retention rates >95% and commanding massive premiums.

Integration Level	Implementation Timeline	Avg Multiple	Premium vs Standalone
Native EHR Module	Pre-integrated (Immediate)	13.0x – 15.0x	+90% Premium
Deep Integration (FHIR)	6 – 9 months	10.0x – 12.0x	+60% Premium
Standard API Integration	12 – 18 months	8.0x – 9.5x	+30% Premium
Standalone (No Integration)	N/A	6.0x – 7.5x	Baseline

The "Native" Advantage

Native integrations allow clinicians to access third-party functionality without leaving the EHR interface. This eliminates the "swivel chair" workflow friction that is the primary cause of clinician burnout, justifying the highest multiples due to superior unit economics and customer stickiness.

RCM Economics: Why Payments Matter



The Revenue Opportunity

\$1.5T Volume

The U.S. healthcare system processes over **\$1.5 trillion** in annual claims volume. RCM vendors are uniquely positioned to capture 3-5% of this transaction volume, creating a massive, recurring revenue stream that scales automatically with provider growth.

Unlike pure software subscriptions, this "SaaS-plus-payments" model generates gross margins of **45-55%**. As providers process more claims, the vendor's revenue compounds without proportional increases in customer acquisition costs.



AI Automation Value

\$22B Opportunity

The most valuable RCM platforms today leverage AI to automate prior authorization and claim denial management—a **\$22 billion** efficiency opportunity. By addressing the top two financial pain points for provider CFOs, these tools become indispensable operational infrastructure.

📈 The "SaaS-Plus" Advantage

- **Multiplied LTV:** Transaction fees can double or triple the Lifetime Value (LTV) compared to software-only contracts.
- **High Stickiness:** Embedded financial workflows create immense switching costs, reducing churn to <5%.
- **Aligned Incentives:** Vendor revenue grows directly with the provider's financial success, fostering long-term partnerships.

Business Models: SaaS vs RCM Mix and Multiples

Valuation multiples are directly correlated with the depth of fintech embeddedness, with end-to-end payment models commanding nearly double the valuation of pure software.

Business Model	Software Rev %	RCM Rev %	Blended Multiple	Valuation Premium
Pure SaaS Platform	90-100%	0-10%	7.5x – 9.0x	Baseline
SaaS + RCM Services	60-70%	30-40%	10.0x – 12.0x	+40% Premium
Full Revenue Cycle	40-50%	50-60%	11.5x – 14.0x	+60% Premium
End-to-End RCM	20-30%	70-80%	13.0x – 16.0x	+80% Premium

The Embedded Fintech Multiplier

Investors are aggressively rewarding platforms that capture the payment flow. Moving from a pure subscription model to an embedded RCM model creates a "SaaS-plus-payments" engine where revenue scales with patient volume, aligning vendor incentives with provider financial success and justifying a massive valuation expansion from 7.5x to 16.0x.

Regulatory Moats & Compliance Costs

Escalating compliance requirements have transformed from cost centers into formidable defensive barriers, protecting incumbents from generalist competitors.


Compliance Requirement	Implementation Cost	Annual Maintenance	Barrier Strength
HIPAA Security Rule	\$2M – \$5M	\$200K – \$500K	Moderate
HITRUST Certification	\$150K – \$400K	\$75K – \$150K	High
Interoperability (Cures Act)	\$300K – \$1M	\$100K – \$300K	Very High
SOC 2 Type II	\$75K – \$200K	\$50K – \$100K	Moderate
State Privacy Laws	\$100K – \$300K	\$50K – \$150K	Growing

Compliance as a Competitive Moat

The regulatory landscape of 2026 demands massive upfront investment. The 21st Century Cures Act's information blocking provisions impose penalties of up to \$1M per violation, creating powerful incentives for providers to stick with established, compliant platforms—driving sector retention rates above 95%.

Value-Based Care Is Repricing Software

% of Healthcare Payments Linked to Value-Based Care



Revenue Generator

Software is shifting from an operational cost to a direct revenue driver. Platforms that improve HEDIS/MIPS scores directly increase provider reimbursement rates, transforming ROI conversations.

Quality Metrics Matter

Valuation premiums of 15-35% are awarded to platforms that can demonstrably improve clinical outcomes. Investors prize solutions that become indispensable for hitting pay-for-performance targets.

Pricing Power

Vendors with proven clinical ROI command higher ACVs and pricing power. The ability to correlate software usage with financial upside for the provider creates immense stickiness and reduces churn.

Clinical Outcome Metrics That Move Multiples

In a value-based care reimbursement environment, SaaS platforms that can demonstrably improve clinical outcomes command significant valuation premiums over operational tools.

Outcome Metric	Measurement Standard	Valuation Impact	Strategic Rationale
Readmission Reduction	10% – 20% Decrease	+15% – 25%	Direct penalty avoidance (HRRP)
Diagnostic Accuracy	25% – 40% Improvement	+20% – 35%	Reduces liability & downstream cost
Cost Per Episode	15% – 25% Reduction	+15% – 30%	Essential for bundled payments
Medication Adherence	15% – 30% Improvement	+10% – 20%	Critical for chronic disease mgmt

The Clinical ROI Premium

Investors are aggressively targeting platforms with proven clinical ROI. Solutions that can validate a **15-25% improvement** in key outcome metrics transform from an operational expense into a revenue generator for providers, warranting valuations 20-35% above the sector median.

Provider Segments: Economics by Buyer Type

Unit economics vary wildly between segments; the mid-market offers the optimal balance of deal velocity and manageable customer concentration risk.

Provider Segment	Avg ACV	Sales Cycle	Annual Churn	Net Revenue Retention
Enterprise Systems (10+ Hospitals)	\$500K+	24 – 36 months	< 5%	125% – 140%
Large Groups (100+ Providers)	\$100K – \$500K	12 – 24 months	8% – 12%	115% – 130%
Mid-Market (50–500 Providers)	\$50K – \$100K	9 – 18 months	12% – 18%	110% – 120%
Small Practices (1–10 Providers)	< \$50K	3 – 9 months	18% – 25%	105% – 115%

The Mid-Market "Sweet Spot"

While Enterprise contracts offer massive ACV and superior retention (<5% churn), the risk of customer concentration and multi-year sales cycles often triggers valuation discounts. The **Mid-Market** segment is currently favored by acquirers for offering predictable growth with efficient CAC payback periods and reduced concentration risk.

Telehealth Stabilizes; RPM Accelerates



Post-Pandemic Normalization

Telehealth adoption has stabilized at **22% of total outpatient visits**, shifting from a growth catalyst to a permanent hybrid care layer. The market has matured, with valuation multiples compressing as basic video visits become commoditized.


Medicare Reimbursement Driver

Remote Patient Monitoring (RPM) is the new growth engine (\$73B market), fueled by aggressive CMS reimbursement rates of **\$62–\$132 PMPM**. With chronic disease driving 85% of costs, payers are actively subsidizing these deployments.

Integration Valuation Premium

Integrated RPM platforms that feed bi-directional data into EHRs command premium valuations (9x–11x) compared to standalone video tools (6x–8x). The value has shifted from "access" (telehealth) to "continuous clinical intelligence" (RPM).

M&A Outlook 2026: Consolidation Accelerates



AI-Driven RCM Targets

Strategic acquirers are prioritizing platforms with AI-driven back-office automation capabilities. Reducing administrative overhead through automated revenue cycle management is the primary synergy driver for 2026 deals.

Integrated Suite Rollups

Private equity firms are actively consolidating point solutions into comprehensive integrated suites. The market is shifting away from fragmented tools toward unified platforms that solve end-to-end clinical and financial workflows.

Strategic Infrastructure Plays

Major incumbents like Optum, Oracle, and large payer organizations are acquiring digital infrastructure assets to control the "digital front door" and value-based care delivery networks, driving premium valuations for infrastructure players.

Lesson 1: Prioritize Deep EHR Integration (12-18 mo)

Valuation Multiplier

Critically Important

EHR integration is the single most important competitive differentiator for healthcare SaaS valuations in 2026. Platforms achieving "native" status command 70-85% valuation premiums over standalone applications, signaling essential workflow utility rather than optional functionality.

Native Status Requirement

Table Stakes

Deep, bi-directional integration with major systems like Epic (App Orchard), Oracle Health (Cerner), and MEDITECH is now a prerequisite for enterprise sales. "Native" status means clinicians access your solution without leaving the primary EHR interface.

12-18 Month Lead Time

Start Early

Founders must prioritize integration well before exploring an exit. The certification and technical validation process typically requires 12-18 months. Start this process early to demonstrate stability and customer adoption metrics during diligence.

Defensibility & Risk

Existential Threat

Standalone applications face increasing displacement risk from integrated competitors. Strategic buyers view non-integrated solutions as "rip-and-replace" candidates, while integrated platforms are valued as sticky, long-term infrastructure assets.

Leverage FHIR-Native Architecture

Utilizing FHIR (Fast Healthcare Interoperability Resources) standards can accelerate integration timelines by 30-40%. Buyers aggressively target platforms built on modern, interoperable architectures that future-proof their tech stack against regulatory shifts.

Lesson 2: Build RCM Into the Core

Valuation Premium

12x - 15x Revenue

Platforms that monetize payment flows command significantly higher multiples (12-15x) compared to pure software counterparts (7-9x). Embedding financial services creates a 40-60% valuation premium by aligning revenue with customer success.

Unit Economics Impact

Double LTV

A 3-5% take rate on payment volume can effectively double Customer Lifetime Value (LTV) without increasing CAC. This "SaaS-plus-payments" model transforms low-margin administrative tools into high-margin fintech platforms.

Implementation Strategy

Build vs. Partner

Founders should aggressively build or partner to embed payment processing, eligibility verification, and prior authorization automation directly into the workflow. Seamless integration reduces friction and increases adoption of financial features.

Minimum Viable Alternative

If becoming a full payment facilitator (PayFac) or native RCM provider isn't immediately feasible, deep integration with leading clearinghouses and billing systems serves as the minimum viable alternative for strategic buyers to validate the workflow-to-payment thesis.

Lesson 3: Prove Clinical Outcomes

The VBC Imperative

65% by 2027

Value-based care (VBC) has become the dominant economic engine, projected to govern 65% of all healthcare payments by 2027. In this environment, software must prove it generates clinical ROI, not just operational efficiency.

Quality Metrics = Revenue

Direct Link

Buyers are prioritizing platforms that directly influence HEDIS, MIPS, and Star Ratings. Because these quality metrics are now tied directly to reimbursement levels, software that improves them transforms from a cost center into a revenue generator.

Evidence Standards

15-25% Gains

To command premium valuations, founders must document measurable improvements. Targets include a 15-25% reduction in readmissions or similar gains in disease-specific outcomes. "Hard evidence" is required to support pricing power.

Validation Rigor

Strategic buyers will rigorously scrutinize clinical efficacy claims during due diligence. Investing in peer-reviewed studies or third-party validation provides the credibility needed to defend premium multiples and accelerates the diligence process.

Lesson 4: Treat Compliance as Product

The Asset Perspective

Critical Infrastructure

Compliance is no longer just overhead—it is a critical asset. Achieving comprehensive HIPAA, SOC 2 Type II, and HITRUST certification has evolved from an optional badge of honor into a binary requirement for entering the enterprise sales funnel.

Resource Allocation

15-20% Budget

Successful founders explicitly allocate 15-20% of engineering and operational resources to maintaining compliance infrastructure. This sustained investment creates a defensive moat against generalist competitors lacking specialized healthcare expertise.

Diligence Accelerator

Deal Velocity

A clean, documented audit history significantly accelerates deal diligence. Conversely, compliance gaps discovered during M&A can kill transactions instantly or trigger massive valuation haircuts of 20-30% due to perceived remediation risks.

The Enterprise Premium

Enterprise health systems are willing to pay significant premiums for certified solutions. Treating compliance as a core product feature—marketed aggressively to CIOs and CISOs—transforms it from a cost center into a key driver of higher ACVs and valuation multiples.

Lesson 5: Target Mid-Market Providers

The Sweet Spot

Optimal Economics

The provider segment of 50–500 physicians represents the valuation "Goldilocks" zone. These organizations are large enough to support healthy Annual Contract Values (ACVs) of \$50,000–\$200,000, yet nimble enough to close deals in 9–18 months—significantly faster than the grueling 2–3 year sales cycles typical of enterprise health systems.

Size vs. Speed

Go-to-Market

This balance of size and speed creates the most efficient path to \$10M ARR. It avoids the "whale hunting" resource drain while providing unit economics far superior to the high-churn SMB segment.

Strategic Benefits

Valuation Impact

Targeting the mid-market allows founders to build a diversified revenue base with superior CAC efficiency. This strategy naturally reduces the customer concentration risk that private equity buyers heavily scrutinize during diligence, resulting in a cleaner exit process.

Private Equity Preference

Acquirers place a significant premium on predictable, repeatable revenue growth. A mid-market focus demonstrates a scalable sales motion that is less susceptible to the "lumpy" revenue patterns and binary risks associated with enterprise-heavy models.

Lesson 6: Specialize by High-Value Specialty

The Vertical Advantage

Deep Moats

Deep specialization in high-value areas like cardiology, orthopedics, or behavioral health commands significant premiums. Investors reward platforms that solve complex, specialty-specific clinical workflows that horizontal generalist platforms cannot address, creating inherent defensibility.

Purpose-Built Workflows

User Stickiness

Purpose-built workflows beat horizontal breadth every time in high-acuity care. Generalist platforms often struggle with the nuance required for specialized treatments, making vertical-specific solutions the preferred choice for providers seeking maximum clinical efficiency.

Become the "OS"

Market Positioning

The ultimate goal is to become the de facto operating system for your specialty. By controlling the core clinical and financial data for a specific provider type, you create an impenetrable moat against broader competitors and become critical infrastructure.

Create Expertise Barriers

Align your product roadmap with high-reimbursement specialties to maximize LTV. Create barriers to entry through deep clinical expertise—rather than just generic software features—to position the company as a scarce, high-value asset in the M&A landscape.

Lesson 7: Plan for Long Sales & Implementation

Extended Timelines

18-42 Months Total

A 12-24 month sales cycle followed by a 6-18 month implementation period is standard for enterprise deals. Failing to account for this extended duration is a fundamental error. Revenue recognition only begins after go-live, creating a significant lag.

Revenue Lag Challenges

Working Capital

The gap between contract signing and revenue realization creates intense working capital pressure. Conservative modeling is essential to prevent missed forecast targets and cash flow crunches during this "valley of death" period.

Operational Maturity

Investor Signal


Demonstrating the ability to manage long working capital cycles signals operational maturity. Founders must build financial models that explicitly account for extended timelines and implementation delays rather than relying on optimistic "signed contract" revenue.

Phased Deployment Strategy

To mitigate implementation risk, phase deployments to accelerate initial time-to-value. Structuring contracts with milestone-based payments or pilot phases can help bridge the working capital gap and validate success early in the 18-month cycle.

Subsector Valuation Dispersion

EV / Revenue Multiple Ranges by Category (Q1 2026)




Clinical Criticality Premium

High-acuity clinical systems (CDS, EHR) command ~40-50% valuation premiums over administrative and commoditized tools.

Key Driver: Direct impact on patient outcomes and Value-Based Care reimbursement creates ROI that justifies premium pricing and valuation.

Integration Premium Ladder (vs Standalone)

Valuation Premium Percentage based on Depth of EHR Integration (Q1 2026)



RCM Model Premium Ladder

Valuation Premium based on Revenue Mix (Q1 2026)



Marketplace Acceleration

Access

Leverage Epic App Orchard and Oracle Health marketplaces for pre-vetted access. Listing on these platforms acts as a stamp of approval, instantly bypassing initial technical vetting hurdles.

Technical Enablement

Speed

Publish FHIR reference architectures to accelerate implementations. Providing clear, pre-built integration schemas demonstrates technical maturity and reduces the burden on hospital IT teams.

Cycle Compression

Velocity

Shorten traditional 24-month enterprise sales cycles to 9-12 months. Marketplace credibility and standardized integrations reduce procurement friction, allowing health systems to pilot faster.

Trust & Compliance

Security

Showcase HITRUST certification prominently in all sales materials. In 2026, security certification is a "go/no-go" gatekeeper; displaying it early prevents deals from stalling in security review.

VBC ROI Alignment

Messaging

Align sales messaging directly with Value-Based Care (VBC) ROI metrics. Shift conversations from features to financial outcomes like HEDIS score improvement and shared savings generation.

Clinical Evidence

Create case studies documenting measurable clinical outcome improvements. Strategic buyers and health systems require proof of efficacy—moving beyond operational efficiency to patient health impact is the key to premium pricing.

Benchmark Summary (Unit Economics)

Healthcare SaaS valuations continue to command significant premiums over general B2B software, driven by workflow embeddedness, payments monetization, and regulatory moats.

Metric Category	Healthcare SaaS Benchmark	Comparative Reference	Strategic Implication
Public Valuation Multiples	9.5x EV/Revenue (Median)	6.7x General B2B SaaS	Sector resilience driven by non-discretionary spend
Private Valuation Range	5.5x – 6.5x EV/Revenue	Premium assets at parity	Competition among PE firms for durable assets
Top Subsector Performance	11.0x – 14.0x (CDS)	10.0x – 13.0x (EHR/EMR)	Clinical criticality drives highest multiples
EHR Integration Premium	+90% for Native Module	+60% for Deep FHIR	Workflow friction elimination is primary value driver
RCM Monetization Premium	+80% for End-to-End	+60% Full Rev Cycle	SaaS-plus-payments economics double LTV
Value-Based Care Impact	+15% – 35% Premium	For proven outcomes	Direct ROI link transforms cost center to revenue driver
Provider Sweet Spot	Mid-Market (\$50k-\$100k ACV)	9-18mo Sales Cycles	Optimal balance of deal size vs velocity

✔ Valuation Premium Drivers

The most valuable healthcare assets in 2026 combine three specific attributes: deep **EHR integration** (native status), embedded **fintech monetization** (RCM), and proven **clinical ROI** (VBC alignment). Platforms achieving this "trifecta" consistently trade above 12x revenue regardless of broader market conditions.

Conclusion: What to Do Now



Integrate Deeply

Achieve native EHR status 12-18 months before exit. Integrated solutions command 70-85% valuation premiums.



Attach to Payments

Build RCM capabilities for 12-15x multiples. Monetizing transaction volume doubles LTV and creates high stickiness.



Prove Clinical ROI

Document 15-25% outcome improvements with third-party validation to secure premium pricing in value-based care.



Invest in Compliance

Allocate 15-20% of resources to HIPAA/HITRUST/SOC2. Treat compliance as a defensive moat, not overhead.



Focus Mid-Market

Target 50-500 physician groups for optimal unit economics, balancing large ACVs with faster sales cycles.



Specialize Vertically

Dominate high-value specialties like cardiology, orthopedics, or behavioral health to build defensible workflow moats.

Sources & Methodology

Report Methodology

This report aggregates data from proprietary transaction databases, public filings, and leading industry research published through Q4 2025. Valuation multiples represent Enterprise Value / LTM Revenue unless otherwise noted. Private market data reflects median quartiles from disclosed Healthcare IT transactions exceeding \$50M EV. Forward-looking statements for Q1 2026 reflect consensus macroeconomic assumptions regarding regulatory shifts (21st Century Cures Act) and reimbursement policy changes (CMS Fee Schedule).

Market Research & Policy

-  **FOCUS Investment Banking**
Healthcare EBITDA Multiples 2025
-  **Precedence Research**
Healthcare IT Market Size 2026
-  **Deloitte**
2026 Global Healthcare Outlook
-  **PwC**
Health Services Deals 2026 Outlook
-  **Bain & Company**
Healthcare IT Investments Report 2026
-  **CMS**
CY 2026 Medicare Physician Fee Schedule

Specialized Industry Analysis

-  **Stedi**
Healthcare RCM Market Map January 2026
-  **Toward Healthcare**
US Healthcare RCM Market 2026
-  **Healthcare IT Today**
2026 RCM Predictions
-  **Auxis**
2026 Revenue Cycle Management Trends
-  **Nixon Law Group**
CMS 2026 Remote Monitoring Reimbursement
-  **Dr. Kumo**
Telehealth Market Growth 2026